Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice

Published:2006-09-18 Issue:12 Volume:26 Page:1702-1713
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Pérez-Caro M,Gutierrez-Cianca N,González-Herrero I,López-Hernández I,Flores T,Orfao A,Sánchez-Martín M,Gutiérrez-Adán A,Pintado B,Sánchez-García I

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/1209968.pdf

Reference48 articles.

1. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. (2003). Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101: 4701–4707.

2. Chabner BA, Roberts Jr TG . (2005). Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 5: 65–72.

3. Chan LC, Karhi KK, Rayter SI, Heisterkamp N, Eridani S, Powles R et al. (1987). A novel abl protein expressed in Philadelphia chromosome-positive acute lymphoblastic leukemia. Nature 325: 635.

4. Choo Y, Sánchez-García I, Klug A . (1994). In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature 372: 642.

5. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL et al. (2005). Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105: 2093–2098.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene in chronic myeloid leukemia and restores normal hematopoiesis;2020-08-05

2. Are Leukaemic Stem Cells Restricted to a Single Cell Lineage?;International Journal of Molecular Sciences;2019-12-19

3. Loss of Pax5 Exploits Sca1-BCR-ABLp190 Susceptibility to Confer the Metabolic Shift Essential for pB-ALL;Cancer Research;2018-02-28

4. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia;Oncotarget;2017-02-09

5. Coupled delivery of imatinib mesylate and doxorubicin with nanoscaled polymeric vectors for a sustained downregulation of BCR-ABL in chronic myeloid leukemia;Biomaterials Science;2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3